GNH USA

Europe — EMA

Medocriptine (Bromocriptine)

GNH USA supplies Medocriptine (Bromocriptine), a dopamine agonist for prolactin, Parkinson's disease and type 2 diabetes therapy. Request a quote for supply.

Bromocriptine

Request sourcing

1
Pack/s

What is Bromocriptine?

Bromocriptine, the active ingredient in Medocriptine, is a dopamine agonist presented as an oral tablet for oral use. It treats hyperprolactinemia, Parkinson's disease and is used as an adjunct in type 2 diabetes management.

GNH USA supplies Medocriptine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Bromocriptine used for?

Medocriptine, a dopamine agonist, acts on dopaminergic pathways to address several endocrine and neurologic conditions. - Hyperprolactinemia: reduces excess prolactin secretion, normalizing menstrual cycles and restoring fertility. - Parkinson's disease: improves motor function and reduces rigidity by stimulating central dopamine receptors. - Type 2 diabetes mellitus (adjunct): enhances glycemic control when added to standard antidiabetic therapy.

What are the side effects of Bromocriptine?

Bromocriptine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Headache - Dizziness - Fatigue - Hypotension - Abdominal discomfort

Serious or Rare Side Effects: - Valvular heart disease - Pulmonary fibrosis - Severe hypotension - Psychosis or hallucinations - Seizures - Hepatic dysfunction

What precautions apply to Bromocriptine?

When prescribing Medocriptine, clinicians should observe several precautionary measures. - Monitor prolactin levels: assess efficacy in hyperprolactinemia. - Evaluate cardiovascular status: watch for hypotension and valvular issues. - Review psychiatric history: risk of psychosis in susceptible patients. - Adjust for hepatic impairment: use with caution in liver disease. - Adjust for renal impairment: consider dose modification in severe renal dysfunction. - Store at ambient temperature: keep in original packaging, protect from moisture.

What does Bromocriptine interact with?

Bromocriptine can interact with other medicines, requiring attention to avoid clinically significant effects.

Major Interactions (Avoid): - Ergot derivatives: combined use may cause severe vasospasm. - Monoamine oxidase inhibitors: risk of hypertensive crisis. - Antipsychotics (dopamine antagonists): may diminish bromocriptine efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): increase bromocriptine plasma levels. - Antihypertensive agents: additive hypotensive effect.

Frequently asked questions

What conditions is Medocriptine used to treat?+
Medocriptine (bromocriptine) is prescribed for hyperprolactinemia, Parkinson's disease, and as an adjunct therapy in type 2 diabetes mellitus to improve glycemic control.
How does bromocriptine work in the body?+
Bromocriptine acts as an agonist at dopamine D2 receptors, suppressing prolactin release from the pituitary and enhancing dopaminergic signaling in the brain, which alleviates motor symptoms in Parkinson’s disease and influences metabolic pathways that aid glucose regulation.
What is the typical dosing regimen for Medocriptine?+
The dosing schedule is individualized; a qualified prescriber determines the appropriate dose, frequency, and titration based on the specific indication, patient response, and tolerability.
Is Medocriptine safe during pregnancy or breastfeeding?+
Safety data are limited; the pregnancy category is unknown, and bromocriptine is generally avoided unless the potential benefit outweighs the risk. Breastfeeding mothers should consult their healthcare provider before use.
How do I order Medocriptine from GNH USA?+
Submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.
How does Medocriptine compare with other dopamine agonists?+
Compared with alternatives such as cabergoline or pramipexole, bromocriptine has a shorter half‑life and may require multiple daily doses, but it is the only dopamine agonist approved for adjunct use in type 2 diabetes, offering a unique metabolic benefit.
What are the recommended storage conditions for Medocriptine?+
Store tablets at ambient temperature, below 25 °C, in the original container, protected from moisture and direct light to maintain potency.
How is Medocriptine administered?+
The medication is taken orally, usually with food to reduce gastrointestinal upset, and should be swallowed whole with a glass of water as directed by the prescriber.
What are the most serious risks associated with Medocriptine?+
Serious adverse events include valvular heart disease, pulmonary fibrosis, severe hypotension, psychosis, seizures, and hepatic dysfunction; patients should be monitored for these conditions throughout therapy.
Who should not take Medocriptine?+
Individuals with known hypersensitivity to bromocriptine, uncontrolled hypertension, recent myocardial infarction, or active psychiatric disorders prone to psychosis should avoid the drug, and it should be used cautiously in patients with hepatic or renal impairment.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Bromocriptine
Route
Oral Use
Manufacturer
Medochemie Ltd.
Origin
EU

Related products

Bromocorn

Bromocorn

Bromocriptine

Farmaceutyczna Spoldzielnia Pracy Filofarm
EU
Bromocriptine Brown & Burk Uk

Bromocriptine Brown & Burk Uk

Bromocriptine

Brown & Burk Uk Limited
EU
Medocriptine

Medocriptine

Bromocriptine

Medochemie Ltd.
EU
Medocriptine

Medocriptine

Bromocriptine

Medochemie Ltd.
EU